Morana Vojnic, MD, MBA, explains how FET-PET imaging's FDA approval is enabling neuro-oncologists to identify ...

Perioperative enfortumab vedotin plus pembrolizumab had a cost-effectiveness ratio of $72,460 per QALY vs radical cystectomy ...

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, discusses how Breakthrough Therapy Designation and ...

FDA final guidance sets a risk-based potency assurance roadmap for cell and gene therapies, spanning development, ...

CT, mouse, and bronchoscopy data link higher body fat to increased lung cancer risk, implicating regulatory T cells as a prevention target. In an interview with Targeted Onc™, Sai Yendamuri, MD, MBA, ...

SABR had higher 3-year all-cause mortality than surgery in early-stage NSCLC (30.3% vs 21.6%) in an emulated target trial; ...

Hoth Therapeutics stopped the phase 2a CLEER-001 trial of topical HT-001 early after an interim review and will seek FDA input on phase 3.

Dirk Schadendorf, MD, discusses where triplet therapy fits for BRAF V600-mutant melanoma following the results of the STARBOARD trial.

Estelamari Rodriguez, MD, MPH, Julia K. Rotow, MD, and Ana I. Velázquez Mañana, MD, MSc, explain how they choose among guideline-preferred ROS1 tyrosine kinase inhibitors (TKIs) for first-line ...

Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.

Updated ENZARAD findings show no significant metastasis-free survival benefit with enzalutamide, although patients receiving pelvic lymph node radiation may benefit from intensification.

Ferdinandos Skoulidis, MD, PhD, explores emerging KRAS-targeted therapies in KRAS-mutated non–small cell lung cancer.